First Horizon Advisors Inc. Has $287,000 Holdings in Boston Scientific Co. (NYSE:BSX)

First Horizon Advisors Inc. lifted its position in shares of Boston Scientific Co. (NYSE:BSX) by 7.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,970 shares of the medical equipment provider’s stock after purchasing an additional 356 shares during the quarter. First Horizon Advisors Inc.’s holdings in Boston Scientific were worth $287,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Bruce G. Allen Investments LLC acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $28,000. Motco increased its holdings in Boston Scientific by 136.3% during the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 372 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 215 shares during the last quarter. Asset Dedication LLC raised its position in Boston Scientific by 42.6% in the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 235 shares during the last quarter. Finally, CNB Bank purchased a new position in Boston Scientific during the third quarter worth about $42,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $72.85 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 0.82. The company has a market capitalization of $106.88 billion, a P/E ratio of 61.22, a PEG ratio of 2.51 and a beta of 0.77. The business has a 50 day moving average price of $68.42 and a 200 day moving average price of $61.42. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Needham & Company LLC lifted their price target on Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. TD Cowen lifted their target price on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. UBS Group boosted their price objective on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Oppenheimer increased their price objective on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a report on Thursday, February 1st. Finally, Raymond James lifted their target price on shares of Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $75.09.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,620,617. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,620,617. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 9,818 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at $3,032,300.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,384 shares of company stock worth $5,395,560. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.